Therapy Areas
Latest News
European Commission approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis
8 May 2026 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced on Friday that the European Commission has approved Sotyktu (deucravacitinib), alone or with methotrexate, for adults with active psoriatic arthritis (PsA) who had an in...
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001
...
Chance Pharma reports NMPA acceptance of NDA for investigational respiratory drug CXG87
8 May 2026 - Chance Pharmaceuticals, a clinical-stage biotech company focused on the research and development of innovative dry powder inhalation (DPI) therapies, announced on Thursday that the Center for Drug Evaluation of China's National Medi...
Halozyme and GSK sign global drug‑delivery collaboration
...
Partner Therapeutics' BIZENGRI receives FDA Commissioner's National Priority Voucher for NRG1 fusion-positive cholangiocarcinoma
7 May 2026 - Biotechnology company Partner Therapeutics Inc (PTx) announced on Wednesday that the US Food and Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) pilot program voucher for BIZENGRI (zenocutuzum...
Diakonos Oncology's DOC1021 granted US FDA Fast Track Designation for unresectable or metastatic cutaneous melanoma
7 May 2026 - Clinical-stage biotechnology company Diakonos Oncology Corp announced on Wednesday that the US Food and Drug Administration (FDA) has granted Fast Track designation to DOC1021 (dubodencel), its first-in-class, patient-derived double-load...
Racura Oncology identifies mechanism of action for (E,E)-bisantrene
...